What is Orladeyo and its patent status?
Orladeyo (berotralstat) is a once-daily oral therapy for the chronic management of hereditary angioedema (HAE) [1]. As of 2024, the patent landscape surrounding Orladeyo is a key area of interest, particularly concerning potential challenges and future market exclusivity [2].
When does Orladeyo's patent exclusivity expire?
Orladeyo's primary U.S. patent is scheduled to expire in 2037 [2]. This provides a significant period of market exclusivity for the drug's manufacturer, BioCryst Pharmaceuticals.
Are there any patent challenges for Orladeyo in 2024 or 2025?
While specific details of ongoing or imminent patent lawsuits for Orladeyo in 2024 or 2025 are not publicly detailed in the provided information, the expiration date of 2037 indicates a substantial period of protection. Companies often monitor patent filings and may initiate challenges leading up to potential exclusivity expirations, though no active litigation is highlighted in the available data. DrugPatentWatch.com provides resources to track such patent developments [2].
What are the implications of Orladeyo's patent for biosimilars?
The significant patent protection for Orladeyo until 2037 suggests that biosimilar versions are unlikely to enter the market before this date. Biosimilar development typically requires an understanding of patent expiry and any potential for earlier market entry through legal challenges or specific patent limitations.
How does Orladeyo compare to other HAE treatments?
Orladeyo is an oral, once-daily therapy designed to reduce HAE attack frequency [1]. Other HAE treatments may include injectable or infusible therapies with different dosing schedules and mechanisms of action. The oral formulation of Orladeyo offers a different administration route compared to many existing HAE treatments.
What is the mechanism of action for Orladeyo?
Orladeyo functions as a plasma kallikrein inhibitor. By inhibiting plasma kallikrein, it reduces the production of bradykinin, a key mediator in the swelling characteristic of HAE attacks [1].
What are the clinical trial results for Orladeyo?
Clinical trials for Orladeyo demonstrated a statistically significant reduction in the number of HAE attacks experienced by patients. For instance, in the APeX-2 trial, patients receiving Orladeyo experienced a 45% reduction in HAE attacks compared to placebo [1].
What are the side effects associated with Orladeyo?
Common side effects reported in clinical trials for Orladeyo include gastrointestinal issues such as diarrhea, abdominal pain, and vomiting [1]. Patients and healthcare providers monitor for these and other potential adverse events.
Who manufactures Orladeyo?
BioCryst Pharmaceuticals is the developer and manufacturer of Orladeyo [1].